AI Prediction Model and Risk Stratification for Lung Metastasis in Colorectal Cancer

Completed

• Conditions: Lung Metastases; Colorectal Cancer
• Interventions: Other: The location of the patient's treatment

• Registration Number: NCT05816902
• Lead Sponsor: Peking Union Medical College

Brief Summary

Background:

To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients.

Method:

The clinicopathological characteristics of 46037 CRC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 2779 CRC patients from a multi-center external validation set were collected retrospectively. After feature selection by univariate and multivariate analyses, six machine learning (ML) models, including logistic regression, K-nearest neighbor, support vector machine, decision tree, random forest, and balanced random forest (BRF), were developed and validated for the LM prediction. The optimization model with best performance was compared to the clinical predictor. In addition, stratified LM patients by risk score were utilized for survival analysis.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-01
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31
• Status Verified: 2023-04
• Study First Submitted: 2023-04-05
• Study First Submitted QC: 2023-04-05
• Last Update Submitted: 2023-04-05
• Study First Posted: 2023-04-18
• Last Update Posted: 2023-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2779

Inclusion Criteria

• patients with pathologic confirmation of a primary CRC diagnosis

Exclusion Criteria

• (1) patients with multiple primary cancers or other malignancies; (2) patients identified via autopsy or death certificate; and (3) patients with uncertain clinical data values

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
validation set 2	The location of the patient's treatment	The validation set 2 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Second Affiliated Hospital of Harbin Medical University.
validation set 1	The location of the patient's treatment	The validation set 1 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College.

Primary Outcome Measures

Name	Time	Method
lung metastasis	through study completion, an average of 3 month	diagnosed with lung metastasis